Arbutus Biopharma Corporation (ABUS)

$1.94

+0.04

(+2.11%)▲

Market is closed - opens 7 PM, 27 Sep 2023

Insights on Arbutus Biopharma Corporation

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.68M → 4.65M (in $), with an average decrease of 30.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -15.46M → -17.09M (in $), with an average decrease of 10.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 90.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 165.8% return, outperforming this stock by 202.8%

Performance

  • $1.91
    $2.00
    $1.94
    downward going graph

    1.55%

    Downside

    Day's Volatility :4.5%

    Upside

    3.0%

    downward going graph
  • $1.86
    $3.15
    $1.94
    downward going graph

    4.12%

    Downside

    52 Weeks Volatility :40.95%

    Upside

    38.41%

    downward going graph

Returns

PeriodArbutus Biopharma CorporationSector (Health Care)Index (Russel 2000)
3 Months
-13.39%
-0.9%
0.0%
6 Months
-36.6%
1.5%
1.0%
1 Year
0.52%
7.1%
6.4%
3 Years
-35.97%
25.9%
19.9%

Highlights

Market Capitalization
318.4M
Book Value
$0.81
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.46
PEG Ratio
0.0
Wall Street Target Price
4.6
Profit Margin
0.0%
Operating Margin TTM
-317.44%
Return On Assets TTM
-23.78%
Return On Equity TTM
-50.68%
Revenue TTM
23.5M
Revenue Per Share TTM
0.15
Quarterly Revenue Growth YOY
-67.30000000000001%
Gross Profit TTM
-45.4M
EBITDA
-73.4M
Diluted Eps TTM
-0.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.43
EPS Estimate Next Year
-0.48
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.11

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Arbutus Biopharma Corporation(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 137.11%

Current $1.94
Target $4.60

Company Financials

FY17Y/Y Change
Revenue
10.7M
↑ 617.64%
Net Income
-84.4M
↓ 78.03%
Net Profit Margin
-788.91%
↑ 24976.62%
FY18Y/Y Change
Revenue
5.9M
↓ 44.44%
Net Income
-57.1M
↓ 32.4%
Net Profit Margin
-959.8%
↓ 170.89%
FY19Y/Y Change
Revenue
6.0M
↑ 1.11%
Net Income
-153.7M
↑ 169.41%
Net Profit Margin
-2.6K%
↓ 1597.56%
FY20Y/Y Change
Revenue
6.9M
↑ 15.02%
Net Income
-63.7M
↓ 58.53%
Net Profit Margin
-921.97%
↑ 1635.39%
FY21Y/Y Change
Revenue
11.0M
↑ 58.92%
Net Income
-76.2M
↑ 19.61%
Net Profit Margin
-693.91%
↑ 228.06%
FY22Y/Y Change
Revenue
39.0M
↑ 255.11%
Net Income
-69.5M
↓ 8.91%
Net Profit Margin
-178.01%
↑ 515.9%
Q1 FY22Q/Q Change
Revenue
12.6M
↑ 292.42%
Net Income
-15.8M
↓ 26.06%
Net Profit Margin
-125.31%
↑ 539.72%
Q2 FY22Q/Q Change
Revenue
14.2M
↑ 13.19%
Net Income
-14.2M
↓ 9.98%
Net Profit Margin
-99.66%
↑ 25.65%
Q3 FY22Q/Q Change
Revenue
6.0M
↓ 58.21%
Net Income
-17.6M
↑ 23.78%
Net Profit Margin
-295.14%
↓ 195.48%
Q4 FY22Q/Q Change
Revenue
6.2M
↑ 4.92%
Net Income
-21.9M
↑ 24.85%
Net Profit Margin
-351.19%
↓ 56.05%
Q1 FY23Q/Q Change
Revenue
6.7M
↑ 7.08%
Net Income
-15.5M
↓ 29.5%
Net Profit Margin
-231.24%
↑ 119.95%
Q2 FY23Q/Q Change
Revenue
4.7M
↓ 30.45%
Net Income
-17.1M
↑ 10.55%
Net Profit Margin
-367.53%
↓ 136.29%
FY17Y/Y Change
Total Assets
237.2M
↓ 14.05%
Total Liabilities
54.7M
↓ 25.0%
FY18Y/Y Change
Total Assets
227.9M
↓ 3.9%
Total Liabilities
27.7M
↓ 49.4%
FY19Y/Y Change
Total Assets
105.5M
↓ 53.69%
Total Liabilities
32.8M
↑ 18.5%
FY20Y/Y Change
Total Assets
137.1M
↑ 29.89%
Total Liabilities
35.1M
↑ 7.08%
FY21Y/Y Change
Total Assets
204.5M
↑ 49.17%
Total Liabilities
35.0M
↓ 0.19%
FY22Y/Y Change
Total Assets
195.4M
↓ 4.43%
Total Liabilities
58.6M
↑ 67.11%
Q1 FY22Q/Q Change
Total Assets
236.9M
↑ 15.84%
Total Liabilities
71.0M
↑ 102.68%
Q2 FY22Q/Q Change
Total Assets
215.8M
↓ 8.88%
Total Liabilities
62.7M
↓ 11.74%
Q3 FY22Q/Q Change
Total Assets
203.8M
↓ 5.58%
Total Liabilities
58.3M
↓ 7.03%
Q4 FY22Q/Q Change
Total Assets
195.4M
↓ 4.11%
Total Liabilities
58.6M
↑ 0.49%
Q1 FY23Q/Q Change
Total Assets
191.2M
↓ 2.15%
Total Liabilities
47.3M
↓ 19.22%
Q2 FY23Q/Q Change
Total Assets
176.8M
↓ 7.53%
Total Liabilities
42.1M
↓ 10.95%
FY17Y/Y Change
Operating Cash Flow
-48.6M
↓ 15.97%
Investing Cash Flow
27.8M
↓ 128.07%
Financing Cash Flow
49.3M
↑ 290.27%
FY18Y/Y Change
Operating Cash Flow
-67.9M
↑ 39.53%
Investing Cash Flow
-4.1M
↓ 114.83%
Financing Cash Flow
55.6M
↑ 12.82%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 4.63%
Investing Cash Flow
28.3M
↓ 786.65%
Financing Cash Flow
37.5M
↓ 32.69%
FY20Y/Y Change
Operating Cash Flow
-51.4M
↓ 27.55%
Investing Cash Flow
-14.9M
↓ 152.61%
Financing Cash Flow
86.7M
↑ 131.59%
FY21Y/Y Change
Operating Cash Flow
-67.5M
↑ 31.28%
Investing Cash Flow
-12.7M
↓ 14.96%
Financing Cash Flow
137.2M
↑ 58.2%
FY22Y/Y Change
Operating Cash Flow
-35.4M
↓ 47.65%
Investing Cash Flow
-74.9M
↑ 491.12%
Financing Cash Flow
31.8M
↓ 76.82%
Q1 FY22Q/Q Change
Operating Cash Flow
20.6M
↓ 205.17%
Investing Cash Flow
-60.1M
↑ 639.51%
Financing Cash Flow
11.5M
↓ 80.57%
Q2 FY22Q/Q Change
Operating Cash Flow
-20.3M
↓ 198.42%
Investing Cash Flow
-13.8M
↓ 76.97%
Financing Cash Flow
113.0K
↓ 99.02%
Q3 FY22Q/Q Change
Operating Cash Flow
1.9M
↓ 109.5%
Investing Cash Flow
-13.7M
↓ 0.67%
Financing Cash Flow
20.6M
↑ 18145.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-37.6M
↓ 2051.69%
Investing Cash Flow
12.7M
↓ 192.31%
Financing Cash Flow
-401.0K
↓ 101.94%
Q1 FY23Q/Q Change
Operating Cash Flow
-27.3M
↓ 27.41%
Investing Cash Flow
16.7M
↑ 31.51%
Financing Cash Flow
20.4M
↓ 5191.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.6M
↓ 28.36%
Investing Cash Flow
1.4M
↓ 91.36%
Financing Cash Flow
4.7M
↓ 76.77%

Technicals Summary

Sell

Neutral

Buy

Arbutus Biopharma Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
-3.96%
-36.6%
0.52%
-35.97%
-80.0%
Moderna, Inc.
Moderna, Inc.
-13.8%
-33.86%
-19.73%
39.08%
427.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.18%
1.46%
19.77%
45.55%
105.03%
Novo Nordisk A/s
Novo Nordisk A/s
-2.09%
18.67%
91.43%
165.4%
285.43%
Seagen, Inc.
Seagen, Inc.
4.8%
8.3%
59.7%
13.46%
176.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
14.01%
23.51%
31.36%
85.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
NA
NA
0.0
-0.43
-0.51
-0.24
0.0
0.81
Moderna, Inc.
Moderna, Inc.
35.31
35.31
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.99
42.99
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.12
27.12
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
Buy
$318.4M
-80.0%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.4B
427.53%
35.31
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
105.03%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$407.6B
285.43%
42.99
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
176.24%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.8B
85.35%
27.12
35.4%

Institutional Holdings

  • BlackRock Inc

    5.95%

  • Two Seas Capital LP

    4.94%

  • Whitefort Capital Management, LP.

    4.83%

  • Vanguard Group Inc

    3.47%

  • Morgan Stanley - Brokerage Accounts

    3.03%

  • Rubric Capital Management LP

    2.03%

Corporate Announcements

  • Arbutus Biopharma Corporation Earnings

    Arbutus Biopharma Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.

Organization
Arbutus Biopharma Corporation
Employees
96
CEO
Mr. William H. Collier
Industry
Health Technology

Discover More

FAQs